Research Progress of Serum Anti-Müllerian Hormone in Patients with Polycystic Ovary Syndrome during Pregnancy

doi:10.12280/gjfckx.20220534

Abstract

Abstract:

Polycystic ovary syndrome (PCOS) is a common reproductive endocrine disorder in women, and serum anti-Müllerian hormone (AMH), as a new indicator for evaluating ovarian reserve, is widely used in the evaluation, diagnosis and treatment of PCOS. With the development of the research on AMH, the research of AMH of PCOS patients during pregnancy has made some progress. It is found that AMH decreases during pregnancy and fluctuates as pregnancy progresses. There is a certain correlation between AMH and androgens during pregnancy of PCOS patients. AMH can be used as a candidate factor for predicting preterm birth in PCOS patients, and provides new ideas and methods for the management of PCOS patients during pregnancy. In addition, it should be noted that the intrauterine environment with high AMH may be an adverse interfering factor in the early life of the offspring of pregnant women with PCOS. PCOS patients belong to a high -risk pregnancy group after pregnancy and face the challenges of various complications during pregnancy. Furthermore, AMH can better guard the maternal and fetal health of PCOS pregnant women, and has broad application prospects in the field of obstetrics. This article focuses on gestation period of PCOS patients and reviews the changes of AMH during pregnancy, the relationship between AMH and androgen, the correlation between AMH and preterm birth, and the condition of AMH in offspring.

Key words: Polycystic ovary syndrome, Pregnancy, Anti-Müllerian hormone, Premature birth, Infant

GAO Jing, GAO Shang, CHENG Wei-wei. Research Progress of Serum Anti-Müllerian Hormone in Patients with Polycystic Ovary Syndrome during Pregnancy[J]. Journal of International Obstetrics and Gynecology, 2022, 49(6): 664-667.

References 32

[1]	Al Wattar BH, Fisher M, Bevington L, et al. Clinical Practice Guidelines on the Diagnosis and Management of Polycystic Ovary Syndrome: A Systematic Review and Quality Assessment Study[J]. J Clin Endocrinol Metab, 2021, 106(8):2436-2446. doi: 10.1210/clinem/dgab232. doi: 10.1210/clinem/dgab232 pmid: 33839790
[2]	Chatzakis C, Tsakmaki E, Psomiadou A, et al. Different pregnancy outcomes according to the polycystic ovary syndrome diagnostic criteria: a systematic review and meta-analysis of 79 studies[J]. Fertil Steril, 2022, 117(4):854-881. doi: 10.1016/j.fertnstert.2021.12.027. doi: 10.1016/j.fertnstert.2021.12.027 pmid: 35120743
[3]	Oldfield AL, Kazemi M, Lujan ME. Impact of Obesity on Anti-Mullerian Hormone (AMH) Levels in Women of Reproductive Age[J]. J Clin Med, 2021, 10(14):3192. doi: 10.3390/jcm10143192. doi: 10.3390/jcm10143192
[4]	Shrikhande L, Shrikhande B, Shrikhande A. AMH and Its Clinical Implications[J]. J Obstet Gynaecol India, 2020, 70(5):337-341. doi: 10.1007/s13224-020-01362-0. doi: 10.1007/s13224-020-01362-0
[5]	Dietz de Loos A, Hund M, Buck K, et al. Antimüllerian hormone to determine polycystic ovarian morphology[J]. Fertil Steril, 2021, 116(4):1149-1157. doi: 10.1016/j.fertnstert.2021.05.094. doi: 10.1016/j.fertnstert.2021.05.094 pmid: 34579824
[6]	Rudnicka E, Kunicki M, Calik-Ksepka A, et al. Anti-Müllerian Hormone in Pathogenesis, Diagnostic and Treatment of PCOS[J]. Int J Mol Sci, 2021, 22(22):12507. doi: 10.3390/ijms222212507. doi: 10.3390/ijms222212507
[7]	Ou M, Xu P, Lin H, et al. AMH Is a Good Predictor of Metabolic Risk in Women with PCOS: A Cross-Sectional Study[J]. Int J Endocrinol, 2021, 2021:9511772. doi: 10.1155/2021/9511772. doi: 10.1155/2021/9511772
[8]	黄春月, 侯丽辉, 杨光, 等. 抗米勒管激素水平与多囊卵巢综合征患者代谢指标的相关性分析[J]. 世界中医药, 2021, 16(14):2171-2176. doi: 10.3969/j.issn.1673-7202.2021.14.020. doi: 10.3969/j.issn.1673-7202.2021.14.020
[9]	Köninger A, Kauth A, Schmidt B, et al. Anti-Mullerian-hormone levels during pregnancy and postpartum[J]. Reprod Biol Endocrinol, 2013, 11:60. doi: 10.1186/1477-7827-11-60. doi: 10.1186/1477-7827-11-60
[10]	Köninger A, Kampmeier A, Schmidt B, et al. Trends in anti-Müllerian hormone concentrations across different stages of pregnancy in women with polycystic ovary syndrome[J]. Reprod Biomed Online, 2018, 37(3):367-374. doi: 10.1016/j.rbmo.2018.05.011. doi: S1472-6483(18)30297-9 pmid: 30146442
[11]	Pankhurst MW, de Kat AC, Jones S, et al. Serum anti-Müllerian hormone levels in women are unstable in the postpartum period but return to normal within 5 months: a longitudinal study[J]. Endocrine, 2021, 71(1):225-232. doi: 10.1007/s12020-020-02491-2. doi: 10.1007/s12020-020-02491-2
[12]	Piltonen TT, Giacobini P, Edvinsson Å, et al. Circulating antimüllerian hormone and steroid hormone levels remain high in pregnant women with polycystic ovary syndrome at term[J]. Fertil Steril, 2019, 111(3):588-596.e1. doi: 10.1016/j.fertnstert.2018.11.028. doi: S0015-0282(18)32223-4 pmid: 30630591
[13]	Valdimarsdottir R, Valgeirsdottir H, Wikström AK, et al. Pregnancy and neonatal complications in women with polycystic ovary syndrome in relation to second-trimester anti-Müllerian hormone levels[J]. Reprod Biomed Online, 2019, 39(1):141-148. doi: 10.1016/j.rbmo.2019.02.004. doi: S1472-6483(19)30101-4 pmid: 31036431
[14]	Kollmann M, Obermayer-Pietsch B, Lerchbaum E, et al. Androgen and Anti-Mullerian Hormone Concentrations at Term in Newborns and Their Mothers with and without Polycystic Ovary Syndrome[J]. J Clin Med, 2019, 8(11):1817. doi: 10.3390/jcm8111817. doi: 10.3390/jcm8111817
[15]	Tata B, Mimouni NEH, Barbotin AL, et al. Elevated prenatal anti-Müllerian hormone reprograms the fetus and induces polycystic ovary syndrome in adulthood[J]. Nat Med, 2018, 24(6):834-846. doi: 10.1038/s41591-018-0035-5. doi: 10.1038/s41591-018-0035-5 pmid: 29760445
[16]	Dewailly D, Barbotin AL, Dumont A, et al. Role of Anti-Müllerian Hormone in the Pathogenesis of Polycystic Ovary Syndrome[J]. Front Endocrinol (Lausanne), 2020, 11:641. doi: 10.3389/fendo.2020.00641. doi: 10.3389/fendo.2020.00641
[17]	Maliqueo M, Lara HE, Sánchez F, et al. Placental steroidogenesis in pregnant women with polycystic ovary syndrome[J]. Eur J Obstet Gynecol Reprod Biol, 2013, 166(2):151-155. doi: 10.1016/j.ejogrb.2012.10.015. doi: 10.1016/j.ejogrb.2012.10.015 pmid: 23122578
[18]	Kallak TK, Hellgren C, Skalkidou A, et al. Maternal and female fetal testosterone levels are associated with maternal age and gestational weight gain[J]. Eur J Endocrinol, 2017, 177(4):379-388. doi: 10.1530/EJE-17-0207. doi: 10.1530/EJE-17-0207 pmid: 28705923
[19]	Malone SA, Papadakis GE, Messina A, et al. Defective AMH signaling disrupts GnRH neuron development and function and contributes to hypogonadotropic hypogonadism[J]. Elife, 2019, 8:e47198. doi: 10.7554/eLife.47198. doi: 10.7554/eLife.47198
[20]	Stegmann BJ, Santillan M, Leader B, et al. Changes in antimüllerian hormone levels in early pregnancy are associated with preterm birth[J]. Fertil Steril, 2015, 104(2):347-355.e3. doi: 10.1016/j.fertnstert.2015.04.044. doi: 10.1016/j.fertnstert.2015.04.044 pmid: 26074093
[21]	Hsu JY, James KE, Bormann CL, et al. Müllerian-Inhibiting Substance/Anti-Müllerian Hormone as a Predictor of Preterm Birth in Polycystic Ovary Syndrome[J]. J Clin Endocrinol Metab, 2018, 103(11):4187-4196. doi: 10.1210/jc.2018-01320. doi: 10.1210/jc.2018-01320 pmid: 30239805
[22]	Kaing A, Jaswa EA, Diamond MP, et al. Highly elevated level of antimüllerian hormone associated with preterm delivery in polycystic ovary syndrome patients who underwent ovulation induction[J]. Fertil Steril, 2021, 115(2):438-446. doi: 10.1016/j.fertnstert.2020.06.015. doi: 10.1016/j.fertnstert.2020.06.015 pmid: 32883514
[23]	Hu KL, Liu FT, Xu H, et al. High antimüllerian hormone levels are associated with preterm delivery in patients with polycystic ovary syndrome[J]. Fertil Steril, 2020, 113(2):444-452.e1. doi: 10.1016/j.fertnstert.2019.09.03. doi: 10.1016/j.fertnstert.2019.09.03
[24]	Stener-Victorin E, Deng Q. Epigenetic inheritance of polycystic ovary syndrome - challenges and opportunities for treatment[J]. Nat Rev Endocrinol, 2021, 17(9):521-533. doi: 10.1038/s41574-021-00517-x. doi: 10.1038/s41574-021-00517-x pmid: 34234312
[25]	Detti L, Christiansen ME, Francillon L, et al. Serum Anti-Müllerian hormone (AMH) in mothers with polycystic ovary syndrome (PCOS) and their term fetuses[J]. Syst Biol Reprod Med, 2019, 65(2):147-154. doi: 10.1080/19396368.2018.1537385. doi: 10.1080/19396368.2018.1537385 pmid: 30428262
[26]	Duan C, Pei T, Li Y, et al. Androgen levels in the fetal cord blood of children born to women with polycystic ovary syndrome: a meta-analysis[J]. Reprod Biol Endocrinol, 2020, 18(1):81. doi: 10.1186/s12958-020-00634-8. doi: 10.1186/s12958-020-00634-8
[27]	Caanen MR, Kuijper EA, Hompes PG, et al. Mass spectrometry methods measured androgen and estrogen concentrations during pregnancy and in newborns of mothers with polycystic ovary syndrome[J]. Eur J Endocrinol, 2016, 174(1):25-32. doi: 10.1530/EJE-15-0699. doi: 10.1530/EJE-15-0699 pmid: 26586837
[28]	Zhou S, Lu D, Wen S, et al. Elevated Anti-Müllerian Hormone Levels in Newborns of Women with Polycystic Ovary Syndrome: a Systematic Review and Meta-analysis Based on Observational Studies[J]. Reprod Sci, 2022, 29(1):301-311. doi: 10.1007/s43032-021-00652-w. doi: 10.1007/s43032-021-00652-w
[29]	Crisosto N, Codner E, Maliqueo M, et al. Anti-Müllerian hormone levels in peripubertal daughters of women with polycystic ovary syndrome[J]. J Clin Endocrinol Metab, 2007, 92(7):2739-2743. doi: 10.1210/jc.2007-0267. doi: 10.1210/jc.2007-0267
[30]	di Clemente N, Racine C, Pierre A, et al. Anti-Müllerian Hormone in Female Reproduction[J]. Endocr Rev, 2021, 42(6):753-782. doi: 10.1210/endrev/bnab012. doi: 10.1210/endrev/bnab012 pmid: 33851994
[31]	Cedars MI. Evaluation of Female Fertility-AMH and Ovarian Reserve Testing[J]. J Clin Endocrinol Metab, 2022, 107(6):1510-1519. doi: 10.1210/clinem/dgac039. doi: 10.1210/clinem/dgac039
[32]	Tadaion Far F, Jahanian Sadatmahalleh S, Ziaei S, et al. Comparison of the umbilical cord Blood's anti-Mullerian hormone level in the newborns of mothers with polycystic ovary syndrome (PCOS) and healthy mothers[J]. J Ovarian Res, 2019, 12(1):111. doi: 10.1186/s13048-019-0583-4. doi: 10.1186/s13048-019-0583-4 pmid: 31735163